Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib inKRAS-Mutant Pancreatic and Colorectal Cancer.
Weisner, J., Landel, I., Reintjes, C., Uhlenbrock, N., Trajkovic-Arsic, M., Dienstbier, N., Hardick, J., Ladigan, S., Lindemann, M., Smith, S., Quambusch, L., Scheinpflug, R., Depta, L., Gontla, R., Unger, A., Muller, H., Baumann, M., Schultz-Fademrecht, C., Gunther, G., Maghnouj, A., Muller, M.P., Pohl, M., Teschendorf, C., Wolters, H., Viebahn, R., Tannapfel, A., Uhl, W., Hengstler, J.G., Hahn, S.A., Siveke, J.T., Rauh, D.
Cancer Res.